Evidence map›Paper›PMID 33499082›Full record

ArticleToxins2021

Kirkiin: A New Toxic Type 2 Ribosome-Inactivating Protein from the Caudex of

Massimo Bortolotti, Stefania Maiello, José M Ferreras, Rosario Iglesias, Letizia Polito, Andrea Bolognesi

Open access · goldAbstract read
In one paragraph

Article in Toxins, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Massimo BortolottiDepartment of Experimental, Diagnostic and Specialty Medicine-DIMES, General Pathology Section, Alma Mater Studiorum-University of Bologna, 40126 Bologna, Italy.ORCID 0000-0001-9030-2237
Stefania MaielloDepartment of Experimental, Diagnostic and Specialty Medicine-DIMES, General Pathology Section, Alma Mater Studiorum-University of Bologna, 40126 Bologna, Italy.
José M FerrerasDepartment of Biochemistry and Molecular Biology and Physiology, Faculty of Sciences, University of Valladolid, E-47011 Valladolid, Spain.ORCID 0000-0003-4816-5878
Rosario IglesiasDepartment of Biochemistry and Molecular Biology and Physiology, Faculty of Sciences, University of Valladolid, E-47011 Valladolid, Spain.ORCID 0000-0002-5021-1733
Letizia PolitoDepartment of Experimental, Diagnostic and Specialty Medicine-DIMES, General Pathology Section, Alma Mater Studiorum-University of Bologna, 40126 Bologna, Italy.ORCID 0000-0001-8051-4981
Andrea BolognesiDepartment of Experimental, Diagnostic and Specialty Medicine-DIMES, General Pathology Section, Alma Mater Studiorum-University of Bologna, 40126 Bologna, Italy.ORCID 0000-0001-7497-4586
University of Bologna · ITUniversidad de Valladolid · ES

Funding

(Consejería de Educación, Junta de Castilla y León) to the GIR ProtIBio Grant VA033G19Fondazione CARISBO Project 2019.0539Pallotti Legacies for Cancer Research no
6 · The paper itself

Abstract

Ribosome-inactivating proteins (RIPs) are plant toxins that irreversibly damage ribosomes and other substrates, thus causing cell death. RIPs are classified in type 1 RIPs, single-chain enzymatic proteins, and type 2 RIPs, consisting of active A chains, similar to type 1 RIPs, linked to lectin B chains, which enable the rapid internalization of the toxin into the cell. For this reason, many type 2 RIPs are very cytotoxic, ricin, volkensin and stenodactylin being the most toxic ones. From the caudex of

Indexed as

Antineoplastic Agents, PhytogenicCell Line, TumorCell SurvivalErythrocyte AggregationHumansMolecular WeightNeuroblastomaPassifloraceaeProtein BiosynthesisProtein Synthesis InhibitorsRibosome Inactivating Proteins, Type 2RibosomesAntineoplastic Agents, PhytogenicProtein Synthesis InhibitorsRibosome Inactivating Proteins, Type 2Adeniaapoptosiskirkiinlectinsneuroblastomaribosome-inactivating proteinsricintoxic enzymes

Identifiers

PMID33499082
PMCPMC7912562
OpenAlexW3122456352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.